THEBIO
- SK Biopharmaceuticals and ProEn Therapeutics plan to advance two preclinical radiopharmaceutical candidates by 2027.
- SK Biopharmaceuticals focuses on small protein-based radiopharmaceuticals for safety and efficacy, responding to global demand through a joint research initiative to advance its therapy business.
[by Yoo, Ha Eun] SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous system and oncology, announced on December 17 a research collaboration agreement with ProEn Therapeutics, a biotech company dedicated to advancing oncology treatments, to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies (RPT).
Under this agreement, both sides seek to advance up to two preclinical candidates for the development of novel radiopharmaceutical drugs by 2027 – the year when SK Biopharmaceuticals aims to become a global leading RPT player via strengthened internal and external resources.
This joint research builds on a series of SK Biopharmaceuticals’ global strategic partnerships, including the in-licensing of a radiopharmaceutical compound and a supply agreement to secure actinium-225, an alpha-particle emitting radioisotope, since the company unveiled its “RPT Roadmap” to gain a competitive edge in the rapidly growing field of nuclear medicine.
SK Biopharmaceuticals will leverage ProEn Therapeutics’ ArtBody™ platform, a dual-target binding technology that incorporates small proteins to identify and target specific tumor antigens – enhancing tumor selectivity – for the development of potential cancer treatments while minimizing damage to healthy tissues. ArtBody™, which has intrinsic advantages of high stability and structural robustness, can be mass-produced using bacteria, making it ideal for industrial applications.
Il-Han Lee, Chief Executive Officer of ProEn Therapeutics, said, “We are pleased to enter this joint research and positive that the ArtBody™ platform will generate synergy with and complement SK Biopharmaceuticals’ radiopharmaceutical therapy business. ProEn Therapeutics will push to produce the best possible outcome that can meet not only the two companies’ expectations but also patients’ needs.”
Donghoon Lee, Chief Executive Officer of SK Biopharmaceuticals, said, “This collaboration with ProEn Therapeutics is significant as the platform technology will help overcome the limitations of existing therapies. We will aim to develop more effective, safer treatments while leading global RPT research and development efforts.”
THEBIO
- SK Biopharmaceuticals and ProEn Therapeutics plan to advance two preclinical radiopharmaceutical candidates by 2027.
- SK Biopharmaceuticals focuses on small protein-based radiopharmaceuticals for safety and efficacy, responding to global demand through a joint research initiative to advance its therapy business.
[by Yoo, Ha Eun] SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous system and oncology, announced on December 17 a research collaboration agreement with ProEn Therapeutics, a biotech company dedicated to advancing oncology treatments, to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies (RPT).
Under this agreement, both sides seek to advance up to two preclinical candidates for the development of novel radiopharmaceutical drugs by 2027 – the year when SK Biopharmaceuticals aims to become a global leading RPT player via strengthened internal and external resources.
This joint research builds on a series of SK Biopharmaceuticals’ global strategic partnerships, including the in-licensing of a radiopharmaceutical compound and a supply agreement to secure actinium-225, an alpha-particle emitting radioisotope, since the company unveiled its “RPT Roadmap” to gain a competitive edge in the rapidly growing field of nuclear medicine.
SK Biopharmaceuticals will leverage ProEn Therapeutics’ ArtBody™ platform, a dual-target binding technology that incorporates small proteins to identify and target specific tumor antigens – enhancing tumor selectivity – for the development of potential cancer treatments while minimizing damage to healthy tissues. ArtBody™, which has intrinsic advantages of high stability and structural robustness, can be mass-produced using bacteria, making it ideal for industrial applications.
Il-Han Lee, Chief Executive Officer of ProEn Therapeutics, said, “We are pleased to enter this joint research and positive that the ArtBody™ platform will generate synergy with and complement SK Biopharmaceuticals’ radiopharmaceutical therapy business. ProEn Therapeutics will push to produce the best possible outcome that can meet not only the two companies’ expectations but also patients’ needs.”
Donghoon Lee, Chief Executive Officer of SK Biopharmaceuticals, said, “This collaboration with ProEn Therapeutics is significant as the platform technology will help overcome the limitations of existing therapies. We will aim to develop more effective, safer treatments while leading global RPT research and development efforts.”